Full Breakdown
Fifth Circuit Blocks Mail-Order Mifepristone, Reinforces In-Person Dispensing
5/4/2026, 10:58:09 AM
Court Ruling and Nationwide Impact
On Friday, the 5th U.S. Circuit Court of Appeals unanimously stayed the FDA’s 2023 REMS that allowed mifepristone to be prescribed online and mailed. The nationwide injunction halts telemedicine abortions even in states where the procedure remains legal, finding Louisiana’s challenge likely to succeed due to procedural flaws in the agency’s rulemaking.
Background & Key Actors
The FDA first eased the in-person dispensing rule for mifepristone in 2021 as a pandemic measure, then made it permanent after the 2022 Dobbs decision. The agency justified remote prescribing by citing “dozens of studies” on safety, but in September 2025 launched a review after acknowledging procedural deficits and a lack of adequate consideration. The lawsuit was filed by Louisiana, represented by state officials including Governor Jeff Landry, while the Guttmacher Institute tracks medication-abortion trends. The three-judge Fifth Circuit panel, appointed by Republican presidents, issued the stay.
Data and Statistics
Mifepristone now accounts for over 60 % of U.S. abortions. Louisiana’s filing cited roughly 1,000 alleged illegal abortions per month and $92,000 in Medicaid costs tied to complications from out-of-state use.
Official Statements & Responses
The FDA, speaking for the Biden administration, said “decades of research and clinical experience confirm the safety of medication abortion” and pledged to finish its pending review. The Fifth Circuit noted the agency “failed to provide a reasoned explanation for abandoning the adverse-event reporting requirement.” No federal officials have offered further comment.
Criticism & Opposition
Reproductive-rights advocates say the ruling eliminates a vital access point for people in rural areas, survivors of intimate-partner violence, and those with disabilities, calling it the most sweeping post-Dobbs threat to abortion. They also accuse Louisiana of using “lies and propaganda” to restrict care.
Verbatim Quotes
- “represents the most sweeping threat to abortion since the overturning of Roe v. Wade” — Kelly Baden, vice president for public policy, Guttmacher Institute
- “Louisiana’s legal attack on mifepristone shamelessly packaged lies and propaganda as an excuse to restrict abortion — and the Fifth Circuit rubber-stamped it,” — Kaye, reproductive-rights advocate
- “another major victory for Louisiana, but more importantly for LIFE!” — Jeff Landry, Governor of Louisiana
- “procedural deficits” and “lack of adequate consideration.” — Fifth Circuit panel
Conflicting Reports & Gaps
The FDA cites “dozens of studies” confirming safety, while the court points to the agency’s admission of insufficient data and missing adverse-event reports. No independent audit of the FDA’s evidence base has been released, leaving a gap in public verification of safety claims.
What’s Next
The FDA’s comprehensive review, launched in September 2025, remains ongoing with no set completion date. Similar challenges to the 2023 REMS are pending in other federal courts, suggesting further litigation could reshape national access to medication abortion.
